135 related articles for article (PubMed ID: 22233356)
1. Granulomatous foreign-body reaction with facial dermal fillers after omalizumab treatment for severe persistent allergic asthma: a case report.
Dammak A; Taillé C; Marinho E; Crestani B; Crickx B; Descamps V
Br J Dermatol; 2012 Jun; 166(6):1375-6. PubMed ID: 22233356
[No Abstract] [Full Text] [Related]
2. Omalizumab 75 mg. Whatever the dosage, the drug should be avoided in severe persistent asthma.
Prescrire Int; 2011 Nov; 20(121):262. PubMed ID: 22066310
[No Abstract] [Full Text] [Related]
3. Omalizumab in the treatment of asthma.
Tan R; Corren J
Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
[TBL] [Abstract][Full Text] [Related]
4. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
5. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Shitrit D; Talker O; Metabichek A; Yaakovi I
Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
[TBL] [Abstract][Full Text] [Related]
6. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
[TBL] [Abstract][Full Text] [Related]
7. Drugs to avoid during pregnancy: omalizumab and montelukast, too many uncertainties.
Prescrire Int; 2014 Feb; 23(146):51. PubMed ID: 24669391
[No Abstract] [Full Text] [Related]
8. Foreign body reaction to facial dermal fillers: case report.
Florin W; Mandel L
J Oral Maxillofac Surg; 2012 Oct; 70(10):2352-5. PubMed ID: 22281129
[TBL] [Abstract][Full Text] [Related]
9. Allergic bronchopulmonary aspergillosis and omalizumab.
Tillie-Leblond I; Germaud P; Leroyer C; Tétu L; Girard F; Devouassoux G; Grignet JP; Prudhomme A; Dusser D; Wallaert B
Allergy; 2011 Sep; 66(9):1254-6. PubMed ID: 21517902
[No Abstract] [Full Text] [Related]
10. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
11. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.
Menzella F; Facciolongo N; Piro R; Formisano D; Roggeri A; Simonazzi A; Castagnetti C; Carbonelli C; Zucchi L
Ther Adv Respir Dis; 2012 Apr; 6(2):87-95. PubMed ID: 22323442
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.
Pace E; Ferraro M; Bruno A; Chiappara G; Bousquet J; Gjomarkaj M
J Asthma; 2011 May; 48(4):387-92. PubMed ID: 21391878
[TBL] [Abstract][Full Text] [Related]
15. Churg-Strauss syndrome in a patient treated with omalizumab.
Cisneros C; Segrelles G; Herráez L; Gonzalez A; Girón R
J Investig Allergol Clin Immunol; 2013; 23(7):515-6. PubMed ID: 24654320
[No Abstract] [Full Text] [Related]
16. Omalizumab under 12 years old: real-life practice.
Pite H; Gaspar Â; Paiva M; Leiria-Pinto P
Allergol Immunopathol (Madr); 2013; 41(2):133-6. PubMed ID: 22560014
[No Abstract] [Full Text] [Related]
17. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
Kupryś-Lipińska I; Kuna P
Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab: a novel steroid sparing agent in eosinophilic granulomatosis with polyangiitis?
Latorre M; Baldini C; Seccia V; Notarstefano C; Della Rossa A; Tani C; Talarico R; Mosca M; Paggiaro PL
Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S91-2. PubMed ID: 23075542
[No Abstract] [Full Text] [Related]
19. [Thrombocytopenia due to omalizumab].
Lopez-Rodriguez JA; Santos Franco L
An Pediatr (Barc); 2014 Jun; 80(6):413-4. PubMed ID: 24246236
[No Abstract] [Full Text] [Related]
20. Granulomatous reactions after injections of multiple aesthetic micro-implants in temporal combinations: a complication of filler addiction.
Rongioletti F; Atzori L; Ferreli C; Pau M; Pinna AL; Mercuri SR; Aste N; Fraitag S
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1188-92. PubMed ID: 25351609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
